MedTrace Logo

Nandrolone Decanoate in the Treatment of Telomeropathies

NCT02055456 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-08-31

No results posted yet for this study

Summary

Decrease in blood cell counts due to deficient bone marrow function, called bone marrow failure, as well as some lung diseases, called idiopathic pulmonary fibrosis, can be caused by genetic defects in telomere biology genes, eventually causing telomere erosion. These disorders are collectively termed "telomeropathies".

There is evidence that male hormones may improve blood cell counts in marrow failure, and these hormones are able to stimulate telomerase function in hematopoietic cells in vitro. We propose this study to the use of male hormone in patients with aplastic anemia and pulmonary fibrosis associated with defects in telomeres.

Conditions

Interventions

DRUG

Nandrolone Decanoate

Sponsors & Collaborators

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico

    collaborator OTHER_GOV

  • University of Sao Paulo

    lead OTHER

Principal Investigators

  • Rodrigo T Calado, MD, PhD · Ribeirao Preto School of Medicine at University of Sao Paulo

  • Diego V Clé, MD · Ribeirao Preto School of Medicine at University of Sao Paulo

  • Ana Beatriz Hortense, MD · Ribeirao Preto School of Medicine at University of Sao Paulo

  • José Antonio Baddini Martinez, MD, PhD · Ribeirao Preto School of Medicine at University of Sao Paulo

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-01
Primary Completion
2017-02-01
Completion
2017-02-01

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02055456 on ClinicalTrials.gov